Published in Oncologist on August 17, 2016
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 4.12
Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract (2012) 4.11
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol (2015) 2.60
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol (2016) 2.06
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol (2015) 1.90
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol (2016) 1.90
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol (2014) 1.39
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol (2011) 1.37
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm (2010) 1.22
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res (2015) 1.15
Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer (2014) 1.11
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res (2015) 1.09
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother (2014) 1.06
Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol (1999) 1.04
Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res (2014) 0.98
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol (2015) 0.98
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res (2016) 0.97
Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer (2014) 0.95
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res (2015) 0.94
Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol (2014) 0.93
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol (2016) 0.92
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer (2015) 0.92
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther (2014) 0.91
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer (2015) 0.88
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer (2015) 0.88
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine (2014) 0.86
Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci (2012) 0.86
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res (2015) 0.85
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. Cancer Immunol Res (2016) 0.84
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med (2015) 0.83
Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother (2015) 0.83
Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf) (2016) 0.82
Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol (2016) 0.82
A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep (2016) 0.80
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79
Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes (2015) 0.79
Clinical trials in melanoma patients with brain metastases. Pigment Cell Melanoma Res (2015) 0.78
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol (2016) 0.77
Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. J Thorac Oncol (2015) 0.77
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol (2016) 0.76